EcoDrugPlus

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSUAMG00000002626
Gene Symbol: HTR5A
2 Cross references
210 Possible Orthologues:

5-Hydroxytryptamine Receptor 6

Ensembl ID : ENSUAMG00000019122
Gene Symbol: HTR6
2 Cross references
114 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSUAMG00000008042
Gene Symbol: ABL1
2 Cross references
202 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSUAMG00000007528
Gene Symbol: ADAM17
2 Cross references
282 Possible Orthologues:

Akt Serine/threonine Kinase 1

Ensembl ID : ENSUAMG00000008765
Gene Symbol: AKT1
2 Cross references
213 Possible Orthologues:

Akt Serine/threonine Kinase 2

Ensembl ID : ENSUAMG00000028436
Gene Symbol: AKT2
2 Cross references
253 Possible Orthologues:

Akt Serine/threonine Kinase 3

Ensembl ID : ENSUAMG00000009488
Gene Symbol: AKT3
2 Cross references
201 Possible Orthologues:

Alk Receptor Tyrosine Kinase

Ensembl ID : ENSUAMG00000015537
Gene Symbol: ALK
2 Cross references
194 Possible Orthologues:

Atp Binding Cassette Subfamily B Member 1

Ensembl ID : ENSUAMG00000016018
Gene Symbol: ABCB1
2 Cross references
161 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 1

Ensembl ID : ENSUAMG00000005688
Gene Symbol: ABCC1
2 Cross references
201 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 9

Ensembl ID : ENSUAMG00000007778
Gene Symbol: ABCC9
2 Cross references
196 Possible Orthologues:

Atpase H+/k+ Transporting Subunit Alpha

Ensembl ID : ENSUAMG00000020718
Gene Symbol: ATP4A
2 Cross references
183 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).